Andreas Maurer

Prof. Dr. Andreas Maurer is Head of the Experimental Neurooncological Radiopharmacy department at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), a leading research institution in Germany focused on cancer research and radiopharmaceutical sciences. His work bridges radiochemistry and neuro-oncology, aiming to develop novel imaging and therapeutic agents for brain tumors.

His research interests lie at the intersection of radiopharmaceutical chemistry, neuro-oncology, and molecular imaging. He specializes in the development and preclinical evaluation of targeted radiotracers, particularly for positron emission tomography (PET), with applications in diagnosing and treating malignant brain tumors. His work emphasizes translational approaches to bring innovative theranostic agents from bench to bedside.

While no recent publications are listed in the provided text, his departmental focus suggests strong activity in radiochemistry, neuroimaging, and targeted radionuclide therapy. His research likely contributes to advancing precision medicine in oncology, particularly for glioblastoma and other central nervous system malignancies.

• Scientific Awards: No awards listed in the provided text.

As head of a research department, Prof. Maurer likely supervises doctoral researchers and postdoctoral fellows, though no named students are provided. His team may be involved in collaborative research projects within HZDR and international networks. He may also participate in grant-funded research in radiopharmaceutical development and neuro-oncology, though specific grants are not mentioned.

The Experimental Neurooncological Radiopharmacy team operates within the Institute of Radiopharmaceutical Cancer Research at HZDR, utilizing advanced radiochemistry labs and preclinical imaging infrastructure to develop and test novel agents for brain tumor targeting.